Suppression of histone deacetylase 3 (HDAC3) enhances apoptosis induced by paclitaxel in human maxillary cancer cells in vitro and in vivo

Biochemical and Biophysical Research Communications

Volumn 396, Issue 2, 2010, Pages 310-316

  Narita, Norihiko ^a   Fujieda, Shigeharu ^a   Kimura, Yuichi ^a   Ito, Yumi ^a   Imoto, Yoshimasa ^a   Ogi, Kazuhiro ^a   Takahashi, Noboru ^a   Tanaka, Takeshi ^a   Tsuzuki, Hideaki ^a   Yamada, Takechiyo ^a   Matsumoto, Hideki ^b  

^a UNIVERSITY OF FUKUI   (Japan)

^b Faculty of Medical Science   (Japan)

Author keywords

Apoptosis; HDAC3; Head and neck cancer; Paclitaxel; Tumor growth

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; HISTONE DEACETYLASE 3; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; RAF PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RELAPSE; CANCER SURVIVAL; CANCER TRANSPLANTATION; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL KILLING; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; ENZYME INACTIVATION; ENZYME INHIBITION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAXILLA CANCER; MICROTUBULE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; HISTONE DEACETYLASES; HUMANS; MAXILLARY NEOPLASMS; MICE; PACLITAXEL; TUBULIN MODULATORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 77952744948     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.04.089     Document Type: Article

References (33)

1. Wani M.C., Taylor H.L., Wall M.E., Coggon P., and McPhail A.T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 93 (1971) 2325-2327
2. Xiao H., Verdier-Pinard P., Fernandez-Fuentes N., Burd B., Angeletti R., Fiser A., Horwitz S.B., and Orr G.A. Insights into the mechanism of microtubule stabilization by Taxol. Proc. Natl. Acad. Sci. USA 103 (2006) 10166-10173
3. Ojima I., Chakravarty S., Inoue T., Lin S., He L., Horwitz S.B., Kuduk S.D., and Danishefsky S.J. A common pharmacophore for cytotoxic natural products that stabilize microtubules. Proc. Natl. Acad. Sci. USA 96 (1999) 4256-4261
4. Jordan M.A., Wendell K., Gardiner S., Derry W.B., Copp H., and Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 56 (1996) 816-825
5. Rowinsky E.K. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu. Rev. Med. 48 (1997) 353-374
6. Leong S.S., Wee J., Tay M.H., Toh C.K., Tan S.B., Thng C.H., Foo K.F., Lim W.T., Tan T., and Tan E.H. Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a Phase II trial using a triplet combination. Cancer Res. 103 (2005) 569-575
7. Johnson L.M., Kayne P.S., Kahn E.S., and Grunstein M. Genetic evidence for an interaction between SIR3 and histone H4 in the repression of the silent mating loci in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA 87 (1990) 6286-6290
8. Lee D.Y., Hayes J.J., Pruss D., and Wolffe A.P. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell 72 (1993) 73-84
9. T. Heinzel, R.M. Lavinsky, T.M. Mullen, M. Soderstrom, C.D. Laherty, J. Torchia, W.M. Yang, G. Brard, S.D. Ngo, J.R. Davie, E. Seto, R.N. Eisenman, D.W. Rose, C.K. Glass, M.G. Rosenfeld, A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression, Nature 387 (1997) 43-48.
10. Haberland M., Montgomery R.L., and Olson E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 10 (2009) 32-42
11. Hartman H.B., Yu J., Alenghat T., Ishizuka T., and Lazar M.A. The histone-binding code of nuclear receptor co-repressors matches the substrate specificity of histone deacetylase 3. EMBO Rep. 6 (2005) 445-451
12. Li D., Yea S., Li S., Chen Z., Narla G., Banck M., Laborda J., Tan S., Friedman J.M., Friedman S.L., and Walsh M.J. Kruppel-like factor-6 promotes preadipocyte differentiation through histone deacetylase 3-dependent repression of DLK1. J. Biol. Chem. 280 (2005) 26941-26952
13. N. Narita, S. Fujieda, M. Tokuriki, N. Takahashi, H. Tsuzuki, T. Ohtsubo, H. Matsumoto, Inhibition of histone deacetylase 3 stimulates apoptosis induced by heat shock under acidic conditions in human maxillary cancer, Oncogene 24 (2005) 7346-7354.
14. Rowinsky E.K., Donehower R.C., Jones R.J., and Tucker R.W. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res. 48 (1988) 4093-4100
15. Bani M.R., Nicoletti M.I., Alkharouf N.W., Ghilardi C., Petersen D., Erba E., Sausville E.A., Liu E.T., and Giavazzi R. Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. Mol. Cancer Ther. 3 (2004) 111-121
16. Mizoguchi H., Komiyama S., Matsui K., Hamanaka R., Ono M., Kiue A., Kobayashi M., Shimizu N., Welgus H.G., and Kuwano M. The response to epidermal growth factor of human maxillary tumor cells in terms of tumor growth, invasion, and expression of proteinase inhibitors. Int. J. Cancer 9 (1991) 738-743
17. Yang W.M., Yao Y.L., Sun J.M., Davie J.R., and Seto E. Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family. J. Biol. Chem. 272 (1997) 28001-28007
18. Park H.J., Lyons J.C., Ohtsubo T., and Song C.W. Acidic environment causes apoptosis by increasing caspase activity. Br. J. Cancer 80 (1999) 1892-1897
19. Riondel J., Jacrot M., Picot F., Beriel H., Mouriquand C., and Potier P. Therapeutic response to taxol of six human tumors xenografted into nude mice. Cancer Chemother. Pharmacol. 17 (1986) 137-142
20. Sugimoto C., Fujieda S., Seki M., Sunaga H., Fan G.K., Tsuzuki H., Borner C., Saito H., and Matsukawa S. Apoptosis-promoting gene (bax) transfer potentiates sensitivity of squamous cell carcinoma to cisplatin in vitro and in vivo. Int. J. Cancer 82 (1999) 860-867
21. O'Dwyer P.J., Moyer J.D., Suffness M., Harrison Jr. S.D., Cysyk R., Hamilton T.C., and Plowman J. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo. Cancer Res. 54 (1994) 724-729
22. Cleveland J.L., Troppmair J., Packham G., Askew D.S., Lloyd P., Gonzalez-Garcia M., Nunez G., and Ihle J.N. U.R. aRapp, v-raf suppresses apoptosis and promotes growth of interleukin-3-dependent myeloid cells. Oncogene 9 (1994) 2217-2226
23. Togi S., Kamitani S., Kawakami S., Ikeda O., Muromoto R., Nanbo A., and Matsuda T. HDAC3 influences phosphorylation of STAT3 at serine 727 by interacting with PP2A. Biochem. Biophys. Res. Commun. 379 (2009) 616-620
24. Eot-Houllier G., Fulcrand G., Watanabe Y., Magnaghi-Jaulin L., and Jaulin C. Histone deacetylase 3 is required for centromeric H3K4 deacetylation and sister chromatid cohesion. Genes Dev. 22 (2008) 2639-2644
25. Wilson A.J., Byun D.S., Popova N., Murray L.B., L'Italien K., Sowa Y., Arango D., Velcich A., Augenlicht L.H., and Mariadason J.M. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J. Biol. Chem. 281 (2006) 13548-13558
26. McDaid H.M., Lopez-Barcons L., Grossman A., Lia M., Keller S., Perez-Soler R., and Horwitz S.B. Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. Cancer Res. 65 (2005) 2854-2860
27. Xia Z., Dickens M., Raingeaud J., Davis R.J., and Greenberg M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270 (1995) 1326-1331
28. Yu X., Guo Z.S., Marcu M.G., Neckers L., Nguyen D.M., Chen G.A., and Schrump D.S. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl. Cancer Inst. 94 (2002) 504-513
29. Lu J., Tan M., Huang W.C., Li P., Guo H., Tseng L.M., Su X.H., Yang W.T., Treekitkarnmongkol W., Andreeff M., Symmans F., and Yu D. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. Clin. Cancer Res. 15 (2009) 1326-1334
30. Tao W., South V.J., Zhang Y., Davide J.P., Farrell L., Kohl N.E., Sepp-Lorenzino L., and Lobell R.B. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 8 (2005) 49-59
31. O'Connor D.S., Wall N.R., Porter A.C., and Altieri D.C. A p34(cdc2) survival checkpoint in cancer. Cancer Cell 2 (2002) 43-54
32. Sasakawa Y., Naoe Y., Inoue T., Sasakawa T., Matsuo M., Manda T., and Mutoh S. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem. Pharmacol. 64 (2002) 1079-1090
33. Hu E., Dul E., Sung C.M., Chen Z., Kirkpatrick R., Zhang G.F., Johanson K., Liu R., Lago A., Hofmann G., Macarron R., de los Frailes M., Perez P., Krawiec J., Winkler J., and Jaye M. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J. Pharmacol. Exp. Ther. 307 (2003) 720-728